CDXC ChromaDex Corp

Price (delayed)

$1.61

Market cap

$120.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$97.97M

ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create ...

Highlights
The company's EPS has surged by 68% YoY
The company's net income has surged by 68% YoY
CDXC's quick ratio has surged by 54% year-on-year but it is down by 2.9% since the previous quarter

Key stats

What are the main financial stats of CDXC
Market
Shares outstanding
75.12M
Market cap
$120.95M
Enterprise value
$97.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.42
Price to sales (P/S)
1.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.18
Earnings
Revenue
$83.37M
EBIT
-$6.88M
EBITDA
-$5.09M
Free cash flow
$5.85M
Per share
EPS
-$0.09
Free cash flow per share
$0.08
Book value per share
$0.36
Revenue per share
$1.11
TBVPS
$0.71
Balance sheet
Total assets
$53.48M
Total liabilities
$26.18M
Debt
$3.79M
Equity
$27.31M
Working capital
$27.74M
Liquidity
Debt to equity
0.14
Current ratio
2.43
Quick ratio
1.66
Net debt/EBITDA
4.52
Margins
EBITDA margin
-6.1%
Gross margin
59.8%
Net margin
-7.8%
Operating margin
-8.2%
Efficiency
Return on assets
-12.1%
Return on equity
-23.3%
Return on invested capital
-48.6%
Return on capital employed
-20.2%
Return on sales
-8.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CDXC stock price

How has the ChromaDex stock price performed over time
Intraday
-3.59%
1 week
5.92%
1 month
6.62%
1 year
-1.83%
YTD
12.59%
QTD
12.59%

Financial performance

How have ChromaDex's revenue and profit performed over time
Revenue
$83.37M
Gross profit
$49.86M
Operating income
-$6.88M
Net income
-$6.47M
Gross margin
59.8%
Net margin
-7.8%
CDXC's operating margin has surged by 75% year-on-year and by 25% since the previous quarter
ChromaDex's net margin has soared by 74% YoY and by 2.5% from the previous quarter
ChromaDex's operating income has surged by 69% YoY and by 22% QoQ
The company's net income has surged by 68% YoY

Growth

What is ChromaDex's growth rate over time

Valuation

What is ChromaDex stock price valuation
P/E
N/A
P/B
4.42
P/S
1.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.18
The company's EPS has surged by 68% YoY
CDXC's price to book (P/B) is 55% lower than its 5-year quarterly average of 9.9 but 5% higher than its last 4 quarters average of 4.2
The equity rose by 30% year-on-year
CDXC's price to sales (P/S) is 68% lower than its 5-year quarterly average of 4.5 and 3.3% lower than its last 4 quarters average of 1.5
The revenue has grown by 21% YoY and by 3% from the previous quarter

Efficiency

How efficient is ChromaDex business performance
The company's return on sales has surged by 72% YoY
The company's return on equity has surged by 72% YoY and by 6% QoQ
ChromaDex's return on assets has surged by 70% YoY and by 4% QoQ
CDXC's return on invested capital has surged by 60% year-on-year but it is down by 19% since the previous quarter

Dividends

What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDXC.

Financial health

How did ChromaDex financials performed over time
The total assets is 104% more than the total liabilities
CDXC's quick ratio has surged by 54% year-on-year but it is down by 2.9% since the previous quarter
The total assets has grown by 17% YoY
ChromaDex's debt is 86% less than its equity
CDXC's debt to equity is down by 33% year-on-year and by 7% since the previous quarter
The equity rose by 30% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.